An interventional study of Smart Bassinet and HALO in Postpartum Depression, Postpartum Anxiety and Sleep Disturbance, sponsored by University of Colorado, Colorado Springs. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by University of Colorado, Colorado Springs · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 32nd largest by planned enrollment of the 198 interventional ones that give a count, is one of 17 that started in 2025, is one of 152 with no phase, reaches primary completion later than 26 of the 48 other live ones, and was the 192nd registered.
570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 342 is above the median of 103 across 455 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Colorado Springs is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
University of Colorado, Colorado Springs has 1 study filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the effectiveness of a Smart Bassinet to prevent/mitigate postpartum mood disorders by augmenting maternal sleep and/or enhancing infant sleep. The investigators will conduct a 2-arm randomized controlled trial (RCT) to compare infant and maternal sleep of infants who use a smart bassinet (SB) or a standard commercially available bassinet (Halo Bassinest Swivel Sleeper 3.0) (usual/traditional care (TAU)). After confirmation of eligibility, participants (N = 342) will randomly be assigned to either the SB or TAU. The investigators hypothesize that use of the SB will be associated with better infant and maternal sleep over a 6-month period, and these mothers will report fewer depressive and anxiety symptoms across the postpartum. The main question[s] it aims to answer [is/are]:
Aim 1: Determine the effect of the SB on infant sleep and maternal sleep. [primary hypothesis or outcome measure 2]? Aim 2: Determine the effect of the SB on maternal postpartum depressive symptoms and evaluate the model that the association between the SB and postpartum depressive symptoms is mediated by both infant and maternal sleep Aim 3: Compare trajectory of immune system function from late pregnancy through postpartum between PPD and non-PPD and between SB and TAU groups Exploratory Aim. Evaluate whether the elevated risk demonstrated by previously identified PPD epigenetic biomarkers at the TTC9B and HP1BP3 genes can be modified by using a SB. The investigators hypothesize that the elevated risk will be reduced in the SB condition compared to TAU.
Military-affiliated pregnant women will be recruited from across the US via social media and advertising. Monthly online questionnaires will be completed by the mother. Objective sleep data will be collected monthly using an actigraph for 1-week from both mother and baby. Blood samples for assay of inflammatory markers will be collected at enrollment, 3- and 6- months postpartum.
The investigators propose to conduct a 2-arm randomized controlled trial (RCT) to compare infant and maternal sleep of infants who use the SB or a standard commercially available bassinet (Halo Bassinest Swivel Sleeper 3.0) (usual/traditional care (TAU)).
The primary objective of this proposal is to randomly assign mother-infant dyads (N = 342) to the SB or the TAU condition and follow them monthly for 6 months. Mothers will complete online surveys monthly regarding infant sleep and behavior, maternal sleep, and maternal depressive symptoms. Prospective subjective and objective sleep data will also be collected from mother and infant for one week each month. This study represents the first empirical study to assess the efficacy of the SB to promote efficient infant sleep, and to assess longitudinal effects on maternal postpartum sleep and mood symptoms. This work is essential since few effective interventions are available that support infant sleep. A secondary objective is to explore maternal biomarkers of PPD, including markers of inflammation and epigenetic biomarkers, and determine if the SB intervention alters immune dysregulation and the risk associated with epigenetic biomarkers of PPD. The rationale stems from evidence regarding dysregulation of the immune system and inflammatory activity as potential mediating pathways between sleep disturbances and health.
This proposal will address the following aims:
Aim 1: Determine the effect of the SB on infant sleep and maternal sleep. Hypothesis 1a: Infants who sleep in the SB will have better sleep (i.e., diary and Brief Infant Sleep Questionnaire as maternally reported) compared to TAU. Outcomes will include maternally reported sleep duration, awakenings, as well as objective assessed (actigraphy) wake after sleep onset (WASO), and sleep onset latency (SOL). Hypothesis 1b: Mothers of infants who sleep in the SB will have better subjectively reported (i.e., diary and Pittsburgh Sleep Quality Index) and objectively assessed (actigraphy) sleep compared to TAU. Outcomes will be the same as the infants.
Aim 2: Determine the effect of the SB on maternal postpartum depressive symptoms and evaluate the model that the association between the SB and postpartum depressive symptoms is mediated by both infant and maternal sleep. Hypothesis 2a: Mothers of infants who sleep in the SB will have fewer postpartum depressive symptoms over time (i.e., Edinburgh Postnatal Depression Scale) compared to TAU. Hypothesis 2b: The SB improves infant sleep, which then predicts better maternal sleep, and thereby predicts lower maternal depressive symptoms.
Aim 3: Compare trajectory of immune system function from late pregnancy through postpartum between PPD and non-PPD and between SB and TAU groups. Hypothesis 3: Peripheral cytokines, immune cells, and stimulated cytokine profiles of women with PPD assessed in late pregnancy, 3- and 6- months postpartum, will indicate greater innate immune activity compared to those who do not develop PPD. Hypothesis 3b: Mothers of infants who sleep in the SB will exhibit less innate immune dysfunction than TAU mothers.
Exploratory Aim. Evaluate whether the elevated risk demonstrated by previously identified PPD epigenetic biomarkers at the TTC9B and HP1BP3 genes can be modified by using a SB. The investigators hypothesize that the elevated risk will be reduced in the SB condition compared to TAU.
Participants. Eligible Pregnant women (N = 342) will be enrolled and randomly assigned to SB or TAU stratified by epigenetic status in the late 3rd trimester and followed longitudinally every month for 6 months. Inclusion criteria: History of depression; singleton gestation; 18-45 years of age; ability to communicate during the screening process; access to a computer, responsive phone, or tablet with internet service; and willing to use the bassinet they are randomized to. Exclusion criteria: clinical confirmation of any current psychopathology (depression, anxiety, suicidal intent, bipolar disorder, etc.), use of psychotropic or sleep medications, multiple gestations, pregnancy/birth complications that would interfere with bassinet use, plans to co-sleep with infant exclusively, tobacco, alcohol, or substance abuse during pregnancy. Self-reported, untreated comorbid sleep disorders, including narcolepsy, periodic leg movement disorder, and/or obstructive sleep apnea.
Initial clinical assessment of depression: Psychopathology will be assessed over the phone using The Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV).
Randomization. Mothers-infant dyads (up to N = 342) will be randomly assigned to conditions by using a random number generating program found on a widely used and reputable website (www.randomizer.org)". This will further allow for comparability between the SB and current usual care/common sleep arrangements. The investigators will perform 1:1 randomization, stratifying for epigenetic status. The SB will be shipped to participants and returned at the expense of Happiest Baby, Inc. TAU participants will be shipped the Halo Bassinest Swivel Sleeper bassinet.
Data Collection. For each assessment, all participants will receive an email with a REDCap link for online data collection. To mitigate and minimize the possibility of missing data in the measures, electronic questionnaires will be programmed to prevent skipping questions. In addition, participants will receive a monthly package containing two actigraphs, maternal sleep diaries, the Baby's Day Diary, a certified blood mailer with tubes, and a prepaid return envelope.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The SB responds to an infant who is fussing or crying by initiating "swaying" movement and "shushing" sounds with white noise that incrementally increase until the infant calms or the caregiver shuts it off. It will help babies transition into life outside of the womb with ease, enabling them to feel safe and secure, which translates to more sleep.
Device: Smart Bassinet
The HALO is a commercially available bassinet that does not have any robotic/responsive actions incorporated within it.
Device: HALO
The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
Also known as: Robotic, responsive bassinet, SNOO
The HALO is a commercially available bassinet
Maternal Mood
Assessment of depressive and anxiety symptoms across the first 6 months postpartum
Time frame: 0-6 months postpartum
Maternal Sleep
Assessment of sleep across the first 6 months postpartum
Time frame: 0-6 months postpartum
Infant Sleep
Assessment of infant sleep across the first 6 months postpartum
Time frame: 0-6 months postpartum
Maternal Inflammation
Assessment of changes in maternal inflammation
Time frame: late pregnancy, 3 & 6 months postpartum
Epigenetic biomarkers at the TTC9B and HP1BP3 genes
Evaluate whether the elevated risk previously demonstrated can be modified by using a SB.
Time frame: assess markers at Baseline (Late pregnancy)
Plan to share: No — The degree to which we share will be based on the US Army's decision.
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.
Of 259 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 31 months is above that.
Counting every sponsor, half of 265 studies reached it within 23 months; a quarter within 11 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Colorado Springs